| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||||
Net income (loss) | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Net income | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Adjustments to reconcile net (loss) income to net cash provided by operating activities: | ||||||||
Depreciation, including patient equipment depreciation | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Equity-based compensation | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Deferred income tax | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Change in fair value of interest rate swaps, net of reclassification adjustment | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Change in fair value of contingent consideration | ||||||||
0 | - | - | - | - | - | - | - | - |
Amortization of deferred financing costs | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Write-off of deferred financing costs | ||||||||
- | - | - | - | 0 | - | - | - | - |
Gain on sale of investment | ||||||||
0 | - | - | - | - | - | - | - | - |
Interest income in cash and marketable securities held in Trust Account | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Changes in operating assets and liabilities, net of effects from acquisitions: | ||||||||
Accounts receivable | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Inventory | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Prepaid and other assets | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Accounts payable and accrued expenses | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Prepaid expenses | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Accounts payable | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Accrued expenses | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Accrued expenses - related parties | ||||||||
- | - | - | - | - | - | - | - | 0 |
Income tax payable | ||||||||
- | - | - | - | - | - | - | - | 0 |
Net cash provided by operating activities | ||||||||
68,565 | 60,417 | 67,923 | 68,172 | 85,039 | 68,426 | 0 | 0 | 0 |
Cash flows from investing activities: | ||||||||
Purchases of equipment and other fixed assets | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Proceeds from sale of investment | ||||||||
0 | - | - | - | - | - | - | - | - |
Payments for business acquisitions, net of cash acquired | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Principal deposited in Trust Account | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Net cash used in investing activities | ||||||||
-170,020 | -84,869 | 154,498 | 154,363 | 127,536 | -96,283 | 0 | 0 | 0 |
Cash flows from financing activities: | ||||||||
Proceeds from borrowings on long-term debt and lines of credit | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Repayments on long-term debt and lines of credit | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Payments on capital leases | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Proceeds from issuance of promissory note payable | ||||||||
- | - | - | - | 0 | - | 0 | 0 | 0 |
Proceeds from issuance of members' interests | ||||||||
- | - | - | - | 0 | - | - | - | - |
Repayment of notes payable to related parties | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Proceeds received from initial public offering | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Payments for equity issuance costs | ||||||||
- | - | - | - | 0 | - | 0 | 0 | 0 |
Payments of deferred financing costs | ||||||||
- | - | - | - | 0 | - | - | - | - |
Distributions to members | ||||||||
- | - | - | - | 0 | - | - | - | - |
Payment of contingent consideration | ||||||||
- | - | - | - | 0 | - | - | - | - |
Payments for redemption of members' interest | ||||||||
- | - | - | - | 0 | - | - | - | - |
Proceeds received from private placement | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Net cash provided by (used in) financing activities | ||||||||
0 | - | - | - | -202,931 | 48,768 | 0 | 0 | 0 |
Net change in cash and cash equivalents | ||||||||
33,293 | 51,692 | 0 | 0 | 0 | - | - | - | - |
Deferred underwriting commissions charged to equity in connection with the initial public offering | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Deferred offering costs charged to equity upon completion of the initial public offering | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Value of common stock subject to possible redemption | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Change in value of common stock subject to possible redemption | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Supplemental disclosures: | ||||||||
Cash paid for interest | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Cash paid for income taxes | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Net change in cash | ||||||||
- | - | - | - | - | - | - | - | 0 |
Noncash investing and financing activities: | ||||||||
Equipment acquired under capital lease obligations | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Unpaid equipment and other fixed asset purchases at end of year | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Equity consideration issued in connection with an acquisition | ||||||||
0 | - | - | - | - | - | - | - | - |
Contingent purchase price in connection with acquisitions | ||||||||
- | - | - | - | 0 | - | - | - | - |
Seller note issued in connection with an acquisition | ||||||||
- | - | - | - | 0 | - | - | - | - |